Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

October 2024

Efficacy and safety of current therapies for difficult-to-treat rheumatoid arthritis: a systematic review and network meta-analysis

Journal of Translational Medicine 2024;22:795

Su Q-Y,

Luo J,

Zhang Y,

Li Q,

Jiang Z-Q,

Wen Z-R,

Wang Y-Y,

Shi M-R,

Zhang S-X

Su et al. conducted a comprehensive systematic review and network meta-analysis to assess the efficacy and safety of therapies for difficult-to-treat (D2T) RA. They found that tocilizumab and rituximab had superior efficacy and safety profiles, with 8mg every 4 weeks of tocilizumab identified as the optimal therapeutic dose.

Keywords:

September 2024

A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis

Br J Dermatol. 2024 Aug 14;191:336-343 doi:10.1093/bjd/ljae062

Cai L,

Jiang C,

Zhang G,

Fang H,

Wang J,

Li Y,

Xu H,

Xiao R,

Ding Y,

Huang K,

Zhang C,

Zhang L,

Chen B,

Duan X,

Pan W,

Han G,

Chen R,

Liu L,

Zhang S,

Tao J,

Pang X,

Yu J,

Wang H,

Zhao Y,

Li C,

Kang X,

Qin L,

Zhu X,

Su J,

Li S,

Yang C,

Feng W,

Lei T,

Jiang S,

Fang R,

Lin M,

Lu Q,

Xu C,

Wang W,

Zhang J

Cai et al. demonstrated that xeligekimab significantly improved the Psoriasis Area and Severity Index (PASI) scores in patients with moderate-to-severe plaque psoriasis, with 90.7% achieving PASI 75 at week 12. Xeligekimab was well-tolerated with no unexpected safety concerns.

Keywords:

May 2024

Efficacy and safety of bimekizumab in the treatment of psoriatic arthritis: A systematic review and meta-analysis

doi: 10.1080/14740338.2024.2343017 Epub ahead of print

Su QY,

Yang L,

Cao TY,

Dang HY,

Han ZC,

Cao JJ,

Zhang HY,

Cheng T,

Zhang SX,

Huo YH Expert Opin Drug Saf 2024;23:1–9

Bimekizumab was superior to placebo in achieving ACR, MDA, and PASI outcomes and had an acceptable safety profile. This meta-analysis also showed that 160mg and 320mg doses of bimekizumab were both superior to placebo in achieving these outcome measures.